NCT07210047 - Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

January 31, 2028

Conditions

Multiple Myeloma Refractory

Interventions

BIOLOGICAL

HuL001-10 mg/kg

Anti-ENO1 monoclonal antibody

BIOLOGICAL

HuL001-15 mg/kg

Anti-ENO1 monoclonal antibody

DRUG

Lenalidomide and Dexamethasone

Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM)

Trial Locations (1)

Far Eastern Memorial Hospital, Taipei